A prospective randomized study was conducted to determine whether amifostine (Ethyol)
reduces the rate of severe esophagitis and hematologic and pulmonary toxicity associated …

PURPOSE: To determine the ability of amifostine to reduce the severity and/or incidence of
the acute toxicities of concurrent chemotherapy and radiotherapy (RT) for non–small-cell …

Twenty-four patients with non-small cell lung cancer received induction chemotherapy
(paclitaxel, carboplatin) followed by concurrent thoracic irradiation (RT) and weekly …

Radiotherapy (RT) or radiochemotherapy is the treatment of choice for patients with
medically or technically inoperable non-small cell lung cancer (NSCLC) localized to the …

Purpose: Greater toxicities have been recognized to be a consequence of combined
chemotherapy and radiotherapy in the treatment of locally advanced non–small-cell lung …

Purpose: This multicenter trial investigated whether daily pretreatment with amifostine (A)
could reduce the incidence of acute and late lung toxicity and esophagitis without affecting …

Esophagitis is a major toxicity of chemoradiotherapy for lung cancer. Twenty-four patients
with non–smallcell lung cancer received induction chemotherapy (paclitaxel/carboplatin) …

PURPOSE: Radiochemotherapy (RCT) is an effective treatment for locally advanced non–
small-cell lung cancer (NSCLC), but can be limited by acute and late toxicities (esophagitis …

INTRODUCTION: We report the long-term results of RTOG 9801, a randomized trial
investigating the ability of amifostine, a radioprotector, to reduce chemoradiation-induced …

Radiochemotherapy (RCT) is an effective treatment for locally advanced non-small cell lung
cancer, but can be limited by acute and late toxicities (esophagitis, pneumonitis, and …